血脂异常,一种意味着高心血管风险的疾病,对其潜在的营养干预措施进行了广泛的研究,包括功能性食品。这项研究旨在研究纳豆激酶红曲补充剂(NMSs)对血脂异常患者心血管生物标志物和颈动脉内膜中层厚度(CIMT)的影响。共有113名符合条件的受试者被随机分配接受NMS或安慰剂(分别为55和58)。经过120天的干预,总胆固醇(TC)有显著的平均绝对变化,低密度胆固醇(LDL-C),非高密度胆固醇(非HDL-C),低密度胆固醇与高密度胆固醇之比(LDL-C与HDL-C之比),值为-0.52(95%CI:-0.51至-0.54)mmol/L,-0.43(95%CI:-0.45至-0.41)mmol/L,-0.52(95%CI:-0.52至-0.52)mmol/L,和-0.29(95%CI:-0.30至-0.28)mmol/L,分别,两组之间。然而,甘油三酯(TG)没有发现显著差异,高密度胆固醇(HDL-C),和CIMT。此外,在使用协方差模型分析校正各种混杂因素后,血脂和CIMT的结果基本保持不变.凝血没有显著差异,肝功能,肾功能,或其他指标。无干预相关不良事件,如口腔溃疡,流口水,和胃痛,被报道。研究结果表明,NMS可以改善血脂水平(TC,LDL-C,非HDL-C,和LDL-C与HDL-C的比率)没有不良事件的发生。然而,它没有显著影响血清TG,HDL-C,和CIMT。
Dyslipidemia, a condition implying high cardiovascular risks, has been widely studied on its potential nutrition interventions, including functional foods. This
study aims to examine the effect of nattokinase monascus supplements (NMSs) on cardiovascular biomarkers and carotid intima-media thickness (CIMT) in patients with dyslipidemia. A total of 113 eligible subjects were randomly assigned to receive either NMSs or a placebo (55 and 58, respectively). After a 120-day intervention, there were significant mean absolute changes in total cholesterol (TC), low-density cholesterol (LDL-C), non-high-density cholesterol (non-HDL-C), and low-density cholesterol to high-density cholesterol ratio (LDL-C to HDL-C ratio), with values of -0.52 (95% CI: -0.51 to -0.54) mmol/L, -0.43 (95% CI: -0.45 to -0.41) mmol/L, -0.52 (95% CI: -0.52 to -0.52) mmol/L, and -0.29 (95% CI: -0.30 to -0.28) mmol/L, respectively, between the two groups. However, no significant differences were found in triglycerides (TGs), high-density cholesterol (HDL-C), and CIMT. Furthermore, the results for lipids and CIMT remained essentially unchanged after adjusting for various confounding factors using the analysis of covariance model. There were no significant differences in coagulation, liver function, renal function, or other indicators. No intervention-related adverse events, such as mouth ulcers, drooling, and stomach pain, were reported. The
study results demonstrate that NMSs can ameliorate lipid levels (TC, LDL-C, non-HDL-C, and the LDL-C to HDL-C ratio) without the occurrence of adverse events. However, it did not significantly affect serum TG, HDL-C, and CIMT.